nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.06.2011 | Original Article

Feasibility of ⁶²Cu-ATSM PET for evaluation of brain ischaemia and misery perfusion in patients with cerebrovascular disease

verfasst von: Makoto Isozaki, Yasushi Kiyono, Yoshikazu Arai, Takashi Kudo, Tetsuya Mori, Rikiya Maruyama, Ken-ichiro Kikuta, Hidehiko Okazawa

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

[⁶²Cu]Diacetyl-bis(N ⁴-methylthiosemicarbazone) (⁶²Cu-ATSM) was used to evaluate brain haemodynamic impairment in patients with cerebrovascular disease (CVD) as a simplified evaluation method. The tracer distribution was compared with haemodynamic parameters obtained by ¹⁵O positron emission tomography (PET).

Methods

Ten patients with major cerebral arterial occlusive disease (aged 66 ± 7 years) underwent PET with ⁶²Cu-ATSM and ¹⁵O tracers (¹⁵O-water, ¹⁵O₂ and C¹⁵O). Seven healthy volunteers also underwent ⁶²Cu-ATSM PET as normal controls. After the injection of ⁶²Cu-ATSM, 20-min dynamic PET data acquisition was started. Early- and delayed-phase images of ⁶²Cu-ATSM were obtained by averaging the initial 3-min and the last 10-min frame data, which were used for perfusion and retention images. Cerebral blood flow (CBF), blood volume, metabolic rate of oxygen (CMRO₂) and oxygen extraction fraction (OEF) were measured by ¹⁵O-gas and water studies and compared with early- and delayed-phase ⁶²Cu-ATSM images and delayed to early (D/E) ratio. Regional values were compared after all parametric images were coregistered to individual MRI. The asymmetry index (AI) was also calculated for OEF and Cu-ATSM D/E ratio, and diagnostic ability for detecting misery perfusion was compared.

Results

In the affected hemisphere of the patients, the mean values of haemodynamic parameters were CBF = 33.8 ± 5.9 ml/100 g per min, CMRO₂ = 2.6 ± 0.3 ml/100 g per min and OEF = 48 ± 7%. Standardized uptake values (SUVs) for ⁶²Cu-ATSM in early and delayed phases were 2.00 ± 0.13 and 1.04 ± 0.09 in the ipsilateral hemisphere and 2.13 ± 0.14 and 1.04 ± 0.08 in the contralateral hemisphere, respectively. The early-phase ⁶²Cu-ATSM images corresponded well to CBF images, and the D/E ratio images were similar to OEF images. Regional values obtained from D/E ratio images were significantly correlated with regional OEF. AIs of OEF and D/E ratio showed a significant correlation and diagnostic ability of misery perfusion was slightly better in AI of D/E ratio than that of OEF.

Conclusion

Dynamic PET acquisition with ⁶²Cu-ATSM provided information on CBF distribution and local elevation of OEF in patients with chronic CVD. The findings of the present study showed the feasibility of the noninvasive molecular imaging method for diagnosing misery perfusion with a single venous tracer injection.

Grubb RL Jr, Derdeyn CP, Fritsch SM, Carpenter DA, Yundt KD, Videen TO, et al. Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion. JAMA 1998;280:1055–60.PubMedCrossRef

Yamauchi H, Fukuyama H, Nagahama Y, Nabatame H, Ueno M, Nishizawa S, et al. Significance of increased oxygen extraction fraction in five-year prognosis of major cerebral arterial occlusive diseases. J Nucl Med 1999;40:1992–8.PubMed

Okazawa H, Kudo T. Clinical impact of hemodynamic parameter measurement for cerebrovascular disease using positron emission tomography and ¹⁵O-labeled tracers. Ann Nucl Med 2009;23:217–27.PubMedCrossRef

Takasawa M, Moustafa RR, Baron JC. Applications of nitroimidazole in vivo hypoxia imaging in ischemic stroke. Stroke 2008;39:1629–37.PubMedCrossRef

Markus R, Reutens DC, Kazui S, Read S, Wright P, Chambers BR, et al. Topography and temporal evolution of hypoxic viable tissue identified by ¹⁸F-fluoromisonidazole positron emission tomography in humans after ischemic stroke. Stroke 2003;34:2646–52.PubMedCrossRef

Sarrafzadeh AS, Nagel A, Czabanka M, Denecke T, Vajkoczy P, Plotkin M. Imaging of hypoxic-ischemic penumbra with ¹⁸F-fluoromisonidazole PET/CT and measurement of related cerebral metabolism in aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 2010;30:36–45.PubMedCrossRef

Read SJ, Hirano T, Abbott DF, Sachinidis JI, Tochon-Danguy HJ, Chan JG, et al. Identifying hypoxic tissue after acute ischemic stroke using PET and ¹⁸F-fluoromisonidazole. Neurology 1998;51:1617–21.PubMed

Read SJ, Hirano T, Abbott DF, Markus R, Sachinidis JI, Tochon-Danguy HJ, et al. The fate of hypoxic tissue on ¹⁸F-fluoromisonidazole positron emission tomography after ischemic stroke. Ann Neurol 2000;48:228–35.PubMedCrossRef

Markus R, Reutens DC, Kazui S, Read S, Wright P, Pearce DC, et al. Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival. Brain 2004;127:1427–36.PubMedCrossRef

10.

Markus R, Donnan G, Kazui S, Read S, Reutens D. Penumbral topography in human stroke: methodology and validation of the ‘Penumbragram’. Neuroimage 2004;21:1252–9.PubMedCrossRef

11.

Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with ¹⁸F-fluoromisonidazole and ¹⁵O-H₂O. J Nucl Med 2004;45:1851–9.PubMed

12.

Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155–60.PubMed

13.

Takahashi N, Fujibayashi Y, Yonekura Y, Welch MJ, Waki A, Tsuchida T, et al. Evaluation of ⁶²Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med 2000;14:323–8.PubMedCrossRef

14.

Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, et al. In vivo assessment of tumor hypoxia in lung cancer with ⁶⁰Cu-ATSM. Eur J Nucl Med Mol Imaging 2003;30:844–50.PubMedCrossRef

15.

Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with ⁶⁰Cu-labeled diacetyl-bis(N4- methylthiosemicarbazone). J Nucl Med 2008;49:201–5.PubMedCrossRef

16.

Lohith TG, Kudo T, Demura Y, Umeda Y, Kiyono Y, Fujibayashi Y, et al. Pathophysiologic correlation between ⁶²Cu-ATSM and 18F-FDG in lung cancer. J Nucl Med 2009;50:1948–53.PubMedCrossRef

17.

Fujibayashi Y, Cutler CS, Anderson CJ, McCarthy DW, Jones LA, Sharp T, et al. Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nucl Med Biol 1999;26:117–21.PubMedCrossRef

18.

Takahashi N, Fujibayashi Y, Yonekura Y, Welch MJ, Waki A, Tsuchida T, et al. Copper-62 ATSM as a hypoxic tissue tracer in myocardial ischemia. Ann Nucl Med 2001;15:293–6.PubMedCrossRef

19.

Obata A, Yoshimi E, Waki A, Lewis JS, Oyama N, Welch MJ, et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med 2001;15:499–504.PubMedCrossRef

20.

Ikawa M, Okazawa H, Arakawa K, Kudo T, Kimura H, Fujibayashi Y, et al. PET imaging of redox and energy states in stroke-like episodes of MELAS. Mitochondrion 2009;9:144–8.PubMedCrossRef

21.

Powers WJ. Cerebral hemodynamics in ischemic cerebrovascular disease. Ann Neurol 1991;29:231–40.PubMedCrossRef

22.

DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE. Performance characteristics of a whole-body PET scanner. J Nucl Med 1994;35:1398–406.PubMed

23.

Matsumoto K, Fujibayashi Y, Yonekura Y, Wada K, Takemura Y, Konishi J, et al. Application of the new zinc-62/copper-62 generator: an effective labeling method for ⁶²Cu-PTSM. Int J Rad Appl Instrum B 1992;19:39–44.PubMed

24.

Okazawa H, Yamauchi H, Sugimoto K, Takahashi M, Toyoda H, Kishibe Y, et al. Quantitative comparison of the bolus and steady-state methods for measurement of cerebral perfusion and oxygen metabolism: positron emission tomography study using ¹⁵O-gas and water. J Cereb Blood Flow Metab 2001;21:793–803.PubMedCrossRef

25.

Okazawa H, Tsuchida T, Kobayashi M, Arai Y, Pagani M, Isozaki M, et al. Can the detection of misery perfusion in chronic cerebrovascular disease be based on reductions in baseline CBF and vasoreactivity? Eur J Nucl Med Mol Imaging 2007;34:121–9.PubMedCrossRef

26.

Okazawa H, Kishibe Y, Sugimoto K, Takahashi M, Yamauchi H, et al. Delay and dispersion correction for a new coincidental radioactivity detector, Pico-Count, in quantitative PET studies. In: Senda M, editor. Brain imaging using PET. San Diego: Academic; 2002. p. 15–21.CrossRef

27.

Raichle ME, Martin WR, Herscovitch P, Mintun MA, Markham J. Brain blood flow measured with intravenous H₂ ¹⁵O. II. Implementation and validation. J Nucl Med 1983;24:790–8.PubMed

28.

Mintun MA, Raichle ME, Martin WR, Herscovitch P. Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography. J Nucl Med 1984;25:177–87.PubMed

29.

Isozaki M, Arai Y, Kudo T, Kiyono Y, Kobayashi M, Kubota T, et al. Clinical implication and prognosis of normal baseline cerebral blood flow with impaired vascular reserve in patients with major cerebral artery occlusive disease. Ann Nucl Med 2010;24:371–7.PubMedCrossRef

30.

Kobayashi M, Kudo T, Tsujikawa T, Isozaki M, Arai Y, Fujibayashi Y, et al. Shorter examination method for the diagnosis of misery perfusion using count-based oxygen extraction fraction elevation in ¹⁵O-gas PET. J Nucl Med 2008;49:242–6.PubMedCrossRef

31.

Saita K, Chen M, Spratt NJ, Porritt MJ, Liberatore GT, Read SJ, et al. Imaging the ischemic penumbra with ¹⁸F-fluoromisonidazole in a rat model of ischemic stroke. Stroke 2004;35:975–80.PubMedCrossRef

32.

Takasawa M, Beech JS, Fryer TD, Hong YT, Hughes JL, Igase K, et al. Imaging of brain hypoxia in permanent and temporary middle cerebral artery occlusion in the rat using 18F-fluoromisonidazole and positron emission tomography: a pilot study. J Cereb Blood Flow Metab 2007;27:679–89.PubMed

Titel: Feasibility of 62Cu-ATSM PET for evaluation of brain ischaemia and misery perfusion in patients with cerebrovascular disease
verfasst von: Makoto Isozaki
Yasushi Kiyono
Yoshikazu Arai
Takashi Kudo
Tetsuya Mori
Rikiya Maruyama
Ken-ichiro Kikuta
Hidehiko Okazawa
Publikationsdatum: 01.06.2011
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2011
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-1734-z

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2011

Prediction of left ventricular remodelling by radionuclide imaging

PET/CT and 3-T whole-body MRI in the detection of malignancy in treated oropharyngeal and hypopharyngeal carcinoma

Erratum to: Ultrafast nuclear myocardial perfusion imaging on a new gamma camera with semiconductor detector technique: first clinical validation

Whole-body hybrid PET/MRI: ready for clinical use?

Relationship between infarct size and severity measured by gated SPECT and long-term left ventricular remodelling after acute myocardial infarction

18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres